Key clinical point: Combining a personalized cancer vaccine known as RO7198457 with the immune checkpoint inhibitor atezolizumab induced neoantigen-specific immune responses in most patients with advanced solid tumors.
Major finding: Ex vivo T-cell responses occurred in 73% of patients evaluated (46/63). However, there were only two clinical responses, including one complete response.
Study details: A phase 1b study including 142 patients exposed to the combination of RO7198457 and atezolizumab.
Disclosures: The study was funded by Genentech and BioNTech. The presenting author reported disclosures related to Roche/Genentech, Basilea Pharmaceutica, and Genmab.
Lopez J et al. AACR 2020, Abstract CT301.